Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- Intermediate Risk Early Breast Cancer

Phase 3

Withdrawn

Conditions: Breast Cancer

Interventions: Drug: Placebo
Drug: Ribociclib
Drug: Adjuvant endocrine therapy

First Posted Date: 2017-03-16

Last Posted Date: 2018-03-15

Lead Sponsor: Novartis Pharmaceuticals

Registration Number: NCT03081234

Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- High Risk Early Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: Ribociclib
Drug: Adjuvant endocrine therapy
Drug: Placebo

First Posted Date: 2017-03-13

Last Posted Date: 2021-10-11

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 54

Registration Number: NCT03078751

Locations: 🇺🇸
Memorial Regional Hospital, Hollywood, Florida, United States
🇺🇸
Northside Hospital Central Research Dept., Atlanta, Georgia, United States
🇺🇸
Tennessee Oncology, PLLC, Chattanooga, Tennessee, United States

and more 30 locations

Urine, DNA and Clinical Information Collection From Patients With Alport Nephropathy.

Completed

Conditions: Alport Nephropathy

First Posted Date: 2017-03-08

Last Posted Date: 2018-11-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 68

Registration Number: NCT03074357

Locations: 🇺🇸
Novartis Investigative Site, Minneapolis, Minnesota, United States

Efficacy, Safety and Tolerability of Topically Applied LDE225 Cream (Hedgehog Pathway Inhibitor) in Adult Patients With Nevoid Basal Cell Carcinoma Syndrome (NBCCS)

Phase 2

Withdrawn

Conditions: Basal Cell Carcinoma

Interventions: Drug: LDE225B
Drug: Vehicle

First Posted Date: 2017-03-03

Last Posted Date: 2017-05-05

Lead Sponsor: Novartis Pharmaceuticals

Registration Number: NCT03070691

Locations: 🇬🇷
Novartis Investigative Site, Athens, Greece
🇬🇧
Novartis Investigative site, Manchester, United Kingdom

High Myopia: Extended and Longterm Observation of Pathologic Myopia Patients With the Risk for Developing a Myopic Choroidal Neovascularization (CNV)

Completed

Conditions: Pathologic Myopia

Interventions: Procedure: Observation & Diagnosis

First Posted Date: 2017-03-03

Last Posted Date: 2019-07-19

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 153

Registration Number: NCT03070717

Locations: 🇩🇪
Novartis Investigative Site, Wuerzburg, Germany

A Randomized, Double-blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF Patients

Phase 3

Completed

Conditions: Heart Failure With Preserved Ejection Fraction

Interventions: Drug: sacubitril/valsartan
Drug: Enalapril
Drug: Placebo to match enalapril
Drug: Valsartan
Drug: Placebo to match valsartan
Drug: Placebo to match sacubitril/valsartan

First Posted Date: 2017-02-28

Last Posted Date: 2021-10-11

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 2572

Registration Number: NCT03066804

Locations: 🇬🇧
Novartis Investigative Site, York, United Kingdom

Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS

Phase 1

Completed

Conditions: Leukemia
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Myelodysplastic Syndromes
Preleukemia
Bone Marrow Diseases
Hematologic Diseases
Chronic Myelomonocytic Leukemia

Interventions: Drug: MBG453
Drug: Decitabine
Drug: PDR001
Drug: Azacitidine

First Posted Date: 2017-02-28

Last Posted Date: 2024-08-29

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 241

Registration Number: NCT03066648

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Oregon Health Sciences University Main Center, Portland, Oregon, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

and more 1 locations

Study of Efficacy and Safety of Secukinumab in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis

Phase 3

Completed

Conditions: Plaque Psoriasis

Interventions: Drug: Placebo
Drug: Secukinumab 150 mg s.c.
Drug: Secukinumab 300 mg s.c.

First Posted Date: 2017-02-28

Last Posted Date: 2019-12-30

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 543

Registration Number: NCT03066609

Locations: 🇹🇷
Novartis Investigative Site, Pendik / Istanbul, Turkey

PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC Patients

Phase 1

Terminated

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: PDR001
Drug: Cisplatin
Drug: Carboplatin
Drug: Gemcitabine
Drug: Pemetrexed
Drug: Paclitaxel
Drug: Canakinumab

First Posted Date: 2017-02-27

Last Posted Date: 2022-08-15

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 111

Registration Number: NCT03064854

Locations: 🇺🇸
UCLA Santa Monica Hematology / Oncology SC-2, Santa Monica, California, United States
🇺🇸
Henry Ford Health System SC, Detroit, Michigan, United States
🇺🇸
Stanford Cancer Center SC, Stanford, California, United States

and more 3 locations

Assess Bronchodilator Effect and Safety of Two Doses of QVM149 Compared to a Fixed Dose Combination of Salmeterol/Fluticasone in Patients With Asthma.

Phase 2

Completed

Conditions: Asthma

Interventions: Drug: QVM149 150/50/80 μg o.d.
Drug: QVM149 150/50/160 μg o.d.
Drug: salmeterol/fluticasone FDC 50/500 μg b.i.d.

First Posted Date: 2017-02-24

Last Posted Date: 2021-10-04

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 116

Registration Number: NCT03063086

Locations: 🇬🇧
Novartis Investigative Site, Manchester, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy